ArticleScientific reports2026
Continuous metabolic syndrome score and cardiometabolic multimorbidity risk in three nationwide cohorts.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the prospective association between the continuous metabolic syndrome score (cMetS) and incident cardiometabolic multimorbidity (CMM) across diverse populations. This prospective multicohort study included 7,114 participants from China (CHARLS), 3,400 from the United States (HRS), and 7,380 from the United Kingdom (ELSA), all aged ≥ 45 years and free of CMM at baseline. cMetS was derived from waist circumference, triglycerides, HDL-C, mean arterial pressure, and fasting glucose. Associations were assessed using Cox models, restricted cubic splines, and pooled random-effects meta-analysis. Over a median follow-up of 7, 4, and 6 years in CHARLS, HRS, and ELSA, 574, 170, and 317 incident CMM cases were documented, respectively. After full adjustment, the highest (vs. lowest) cMetS tertile was associated with significantly increased CMM risk (HR = 4.27 in CHARLS, 1.77 in HRS, 1.54 in ELSA). The pooled HR per 1-SD increase in cMetS was 1.35 (95% CI 1.17-1.56). Dose-response relationships were nonlinear in CHARLS but linear in HRS and ELSA. Associations were robust in subgroup and sensitivity analyses. Higher cMetS is consistently associated with increased CMM risk among middle-aged and older adults in three nations, suggesting its potential value for risk stratification, pending further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.